Power Law company profile

Palvella Therapeutics

Biotech & Life Sciences · Radnor Township, United States · Founded 2015 · IPO 2024 Unicorn

Rare disease biopharmaceutical company

Valuation

$1.78B

Market cap · May/2026

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

18 investors on Palvella Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage

Ligand Pharmaceuticals

Series B+ 17 investors entered at this stage

Integrated Finance

Dafna Capital Management

BVF Partners

ADAR1 Capital Management

Samsara BioCapital

Gore Range Capital

Opaleye Management

Agent Capital

Frazier Life Sciences

13 Ventures

BioAdvance

Petrichor

Nolan Capital

Blue Owl Capital

CAM Capital

Adams Street Partners

Nantahala Capital Management

Global footprint

Where Palvella Therapeutics has talent and traffic

Workforce by country

🇺🇸 United States · Radnor Township HQ

Book a demo for the full country breakdown

Web traffic by country

19K monthly visits
across markets

🇺🇸 United States90.5%

🇬🇧 United Kingdom5.8%

🇮🇳 India2.6%

Top 3 markets shown

Market sentiment

What the market is saying about Palvella Therapeutics

An AI-synthesized read of the highest-engagement posts about Palvella Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Palvella Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles